ProCE Banner Activity

Triplets and Quadruple Combination Therapy in Multiple Myeloma: When, Why, and How?

Clinical Thought
With multiple recent approvals, many options exist for treating patients with myeloma. However, selecting therapy for patients relapsing after exposure to multiple therapies remains a challenge.

Released: May 16, 2017

Expiration: May 15, 2018

No longer available for credit.

Share

Faculty

Suzanne Lentzsch

Suzanne Lentzsch, MD, PhD

Director, Multiple Myeloma and Amyloidosis Program
Associate Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Takeda Oncology

Faculty Disclosure

Primary Author

Suzanne Lentzsch, MD, PhD

Director, Multiple Myeloma and Amyloidosis Program
Associate Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Suzanne Lentzsch, MD, PhD, has disclosed that she has received consulting fees from Bristol-Myers Squibb, Novartis, and Takeda.